QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO)(OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) CMO Discusses ONC010, Novel PNKP Target in BioMedWire Podcast
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Chief Medical Officer Dr. Islam Mohamed joined IBN BioMedWire Podcast to discuss lead drug candidate ONC010, the company novel approach to targeting the DNA repair enzyme polynucleotide kinase phosphatase (“PNKP”) and its planned first-in-human clinical program. Mohamed highlighted ONC010 two selectivity mechanisms — synthetic lethality designed to limit drug lethality to cancer cells that have lost PTEN or SHP-1 and nanoparticle delivery intended to concentrate the drug within tumor tissue — as well as preclinical…